Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction

NCT03728426 is registered in ClinicalTrials.gov with Amy C. Sherman, MD as lead sponsor.

NCT NCT03728426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03728426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
Lead sponsor
Amy C. Sherman, MD
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2019
Completion date
March 28, 2022
Enrollment
10 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections